Lepu Biopharma
Founded in Jan 2018 by Dr. Pu Zhongjie, Lepu Biotech focuses on tumor immunotherapy, R&D, production, and sales of targeted therapy drugs.
Launch date
Employees
Market cap
AUD979m
Enterprise valuation
AUD1.0b (Public information from Sep 2024)
Share price
HKD2.96 2157.HK
Songjiang District China (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | 15.6m | 225m | 195m | 277m | - |
| % growth | - | - | - | 1347 % | (13 %) | 42 % | - |
| EBITDA | (371m) | (865m) | (533m) | (133m) | (208m) | (311m) | (114m) |
| % EBITDA margin | - | - | (3423 %) | (59 %) | (107 %) | (112 %) | - |
| Profit | (582m) | (1.0b) | (689m) | (22.1m) | - | - | - |
| % profit margin | - | - | (4425 %) | (10 %) | - | - | - |
| EV / revenue | - | - | 693.8x | 29.5x | 23.6x | 17.4x | - |
| EV / EBITDA | - | - | -20.3x | -49.9x | -22.1x | -15.5x | -30.9x |
| R&D budget | 354m | 791m | 524m | 458m | - | - | - |
| R&D % of revenue | - | - | 3367 % | 203 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | $1.3b | Series B | |
* | N/A | $116m | IPO |
| Total Funding | AUD2.0b | ||